GLS Stock Overview
Engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Glenmark Life Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,082.90 |
| 52 Week High | ₹1,335.10 |
| 52 Week Low | ₹620.20 |
| Beta | 0.16 |
| 11 Month Change | -2.70% |
| 3 Month Change | 4.31% |
| 1 Year Change | 73.18% |
| 33 Year Change | 74.03% |
| 5 Year Change | n/a |
| Change since IPO | 44.68% |
Recent News & Updates
Shareholder Returns
| GLS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.2% | -1.8% | -1.8% |
| 1Y | 73.2% | 41.2% | 27.2% |
Return vs Industry: GLS exceeded the Indian Pharmaceuticals industry which returned 41.2% over the past year.
Return vs Market: GLS exceeded the Indian Market which returned 27.2% over the past year.
Price Volatility
| GLS volatility | |
|---|---|
| GLS Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: GLS has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: GLS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 2,014 | Yasir Rawjee | www.glenmarklifesciences.com |
Glenmark Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies.
Glenmark Life Sciences Limited Fundamentals Summary
| GLS fundamental statistics | |
|---|---|
| Market cap | ₹132.69b |
| Earnings (TTM) | ₹4.24b |
| Revenue (TTM) | ₹22.05b |
31.3x
P/E Ratio6.0x
P/S RatioIs GLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLS income statement (TTM) | |
|---|---|
| Revenue | ₹22.05b |
| Cost of Revenue | ₹10.32b |
| Gross Profit | ₹11.73b |
| Other Expenses | ₹7.50b |
| Earnings | ₹4.24b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 34.56 |
| Gross Margin | 53.21% |
| Net Profit Margin | 19.21% |
| Debt/Equity Ratio | 0% |
How did GLS perform over the long term?
See historical performance and comparison